Avalo to Present at the Jefferies Healthcare Conference
June 01 2023 - 7:00AM
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry
A. Neil, M.D., Chief Executive Officer and Chairman of the Board,
will present at the Jefferies Healthcare Conference on Friday, June
9, 2023 at 11:00 a.m. ET at the Marriott Marquis in New York, NY.
A live webcast of the presentation can be
accessed under the “News/Events” page in the Investors section of
the Company's website at www.avalotx.com.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage
biotechnology company focused on the treatment of immune
dysregulation by developing therapies that target the LIGHT
network.
LIGHT (Lymphotoxin-like,
exhibits Inducible expression, and competes
with HSV Glycoprotein D
for Herpesvirus Entry Mediator (HVEM), a
receptor expressed by T lymphocytes;
also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT
and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β
receptor (TNFRSF3), form an immune regulatory network with two
co-receptors of herpesvirus entry mediator, checkpoint inhibitor B
and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling
network). Accumulating evidence points to the dysregulation of the
LIGHT network as a disease-driving mechanism in autoimmune and
inflammatory reactions in barrier organs. Therefore, we believe
reducing LIGHT levels can moderate immune dysregulation in many
acute and chronic inflammatory disorders.
For more information about Avalo, please
visit www.avalotx.com.
Forward-Looking Statements
This press release may include forward-looking
statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that
are not historical facts. Such forward-looking statements are
subject to significant risks and uncertainties that are subject to
change based on various factors (many of which are beyond Avalo’s
control), which could cause actual results to differ from the
forward-looking statements. Such statements may include, without
limitation, statements with respect to Avalo’s plans, objectives,
projections, expectations and intentions and other statements
identified by words such as “projects,” “may,” “might,” “will,”
“could,” “would,” “should,” “continue,” “seeks,” “aims,”
“predicts,” “believes,” “expects,” “anticipates,” “estimates,”
“intends,” “plans,” “potential,” or similar expressions (including
their use in the negative), or by discussions of future matters
such as: the future financial and operational outlook; the
development of product candidates or products; timing and success
of trial results and regulatory review; potential attributes and
benefits of product candidates; and other statements that are not
historical. These statements are based upon the current beliefs and
expectations of Avalo’s management but are subject to significant
risks and uncertainties, including: Avalo's debt and cash position
and the need for it to raise additional capital in the near future;
drug development costs, timing and other risks, including reliance
on investigators and enrollment of patients in clinical trials,
which might be slowed by COVID-19 or other widespread health
events; reliance on key personnel; regulatory risks; general
economic and market risks and uncertainties, including those caused
by COVID-19 or other widespread health events; and those other
risks detailed in Avalo’s filings with the SEC. Actual results may
differ from those set forth in the forward-looking statements.
Except as required by applicable law, Avalo expressly disclaims any
obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Avalo’s expectations with respect thereto or
any change in events, conditions or circumstances on which any
statement is based.
For media and investor
inquiries
Christopher Sullivan, CFO Avalo Therapeutics,
Inc.ir@avalotx.com410-803-6793
or
Chris BrinzeyICR
WestwickeChris.brinzey@westwicke.com339-970-2843
Avalo Therapeutics (NASDAQ:AVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avalo Therapeutics (NASDAQ:AVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024